Buy Etibo 250mg - Lapatinib Tablets Online, Etibo 250mg

Wishlist(0)

Etibo 250mg - Lapatinib Tablets

Etibo 250mg is a targeted therapy medication used in the treatment of HER2-positive advanced or metastatic breast cancer. It helps slow the growth of cancer cells by blocking specific proteins involved in cancer progression.

Select your size:

250mg

Choose Quantity:

+ Add To Cart

Buy Now

Add to wishlist

Description Product Details

General Information:

Generic Name: Lapatinib

Brand Name: Etibo 250mg

Packing: Bottle of 30 or 60 tablets (varies by manufacturer)

Strength: 250mg

Manufacturer: Natco Pharma Ltd.

Form: Oral Tablets

Category: Anti-cancer, Tyrosine Kinase Inhibitor

Product Intro:

Etibo 250mg contains Lapatinib, a dual tyrosine kinase inhibitor that targets HER2 and EGFR pathways. It is prescribed to patients with advanced breast cancer, particularly those who have previously received other HER2-targeted treatments. Etibo is commonly used in combination with other medications like capecitabine or letrozole.

Uses:

Etibo 250mg is used to treat:

HER2-positive metastatic breast cancer
Hormone receptor-positive and HER2-positive breast cancer
Breast cancer patients resistant to trastuzumab therapy
Breast cancer in combination with capecitabine
Breast cancer in combination with letrozole
Investigational use in other HER2-driven cancers

Storage Instructions:

Store at room temperature below 30°C
Keep away from moisture and direct sunlight
Keep the bottle tightly closed
Keep out of reach of children

How it Works (Mechanism of Action):

Lapatinib inhibits the tyrosine kinase domains of two key receptors: HER2 (ErbB2) and EGFR (ErbB1). This dual inhibition blocks key pathways that drive the growth and survival of cancer cells, particularly in HER2-overexpressing tumors, leading to reduced tumor proliferation.

Side Effects:

Common Side Effects:

Diarrhea
Rash
Fatigue
Nausea
Loss of appetite
Hand-foot syndrome

Severe Side Effects:

Hepatotoxicity (elevated liver enzymes)
Cardiotoxicity (decreased LVEF)
Pulmonary toxicity
QT interval prolongation
Severe skin reactions

Dosage (Typical Recommended Dose):

Standard dosage: 1,250 mg daily (5 tablets of 250mg)
Taken continuously unless directed otherwise by your doctor
May vary when used with other drugs like letrozole or capecitabine

Method of Administration:

Take orally with water
Should be taken on an empty stomach (1 hour before or 1 hour after meals)
Swallow whole; do not crush or chew
Take at the same time each day for best results

Precautions:

Monitor liver function regularly
Cardiac function (e.g., LVEF) should be assessed before and during treatment
Avoid grapefruit juice and alcohol
Use effective contraception during and for at least one week after stopping the medication
Not recommended in pregnancy or breastfeeding

Drug Interactions:

Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase levels
CYP3A4 inducers (e.g., rifampin) may reduce effectiveness
QT-prolonging drugs (e.g., amiodarone) may increase cardiac risks
Antacids and PPIs may affect absorption

Allergies:

Avoid if allergic to Lapatinib or any component of the formulation
Signs of allergy include rash, itching, swelling, dizziness, or difficulty breathing

Overdose Information:

Symptoms may include severe diarrhea, liver damage, or irregular heartbeat
In case of overdose, seek immediate medical attention or contact a poison control center

Missed Dose Instructions:

Take the missed dose as soon as remembered
If close to next dose, skip the missed dose
Do not double the dose to catch up

Additional Notes:

Regular monitoring of liver and heart is essential
Inform your doctor about all medications you're taking
Stay hydrated and follow dietary guidelines if given
Do not stop medication without your doctor's advice